Inhalation repurposing of an approved drug to treat severe asthma
Ended Project Grant Awarded Last action
- Award ID
- R44HL156372
- Recipient
-
Aeon Respire, Inc. UEI UZCNVPKMNCH8
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $9,849,901
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Originally
- Funding
-
- $7,387,300.94 Federal
- $2,462,600.00 Non-federal
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
- Abstract
- The business objective of aeon respire, and the purpose of this sbir project, is to execute key steps towards repurposing niclosamide as a new asthma treatment. The therapeutic rationale for these studies is based on initial findings that niclosamide inhibits an ION channel that is pivotal for airway smooth muscle contraction and mucin hypersecretion. Both of these pathologic processes contribute to airway narrowing and are considered, in addition to inflammation, as the core features of asthma. Existing medications fail to adequately relieve airway narrowing in more severe, treatment refractory patients. In particular, the efficacy of inhaled beta-agonists is compromised at a cellular level by both repeat use desensitization and the indirect effects of inflammation. Therefore, there is need for new treatment approaches. TMEM16A is a calcium-activated chloride channel that regulates calcium signaling in the airways and is required for airway smooth muscle contraction. Niclosamide is an FDA-approved oral drug originally discovered decades ago and safely used as an anti-helminth. IT was recently identified in a high throughput unbiased screen as a specific TMEM16A inhibitor. Niclosamide fully relaxes contracted airways via this mechanism and resists desensitization pathways that undermine the effectiveness of beta-agonists. IT also reduces mucin release induced by asthma- associated activation signals. TMEM16A inhibition with repurposed niclosamide is therefore an attractive new asthma treatment approach and will benefit from the drug's established human safety record. Niclosamide, however, has poor bioavailability and is unlikely to reach TMEM16A in the airways through oral dosing. The first objective of the project is to reformulate niclosamide through particle engineering to enable inhaled dosing. The next objective is to use the new formulation in inhalation studies to confirm the drug reaches its target locally and will open airways provoked by a contractile agent. Additional studies will establish the pharmacokinetic and initial toxicologic profile of inhaled niclosamide. These studies are crucial to test the scientific hypothesis that inhibiting TMEM16A in the airways is a safe and effective approach to open obstructed airways. They also represent important steps required to move the project closer to discussions with the FDA, filing an IND and testing in human studies.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$129 | $0 | |
| Amendment | -$370 | $0 | |
| Amendment | $992,767 | $0 | |
| Amendment | $992,767 | $992,767 | |
| Amendment | $992,767 | $0 | |
| Amendment | $1,193,081 | $0 | |
| Amendment | $1,193,081 | $1,193,081 | |
| Amendment | $1,193,081 | $0 | |
| Amendment | $276,752 | $0 | |
| Amendment | $276,752 | $0 | |
| Original award | $276,752 | $276,752 |
Show all 11
Quick answers
Who received award R44HL156372?
R44HL156372 was awarded to Aeon Respire, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on January 9, 2021.
How much is award R44HL156372 worth?
$9,849,901 has been obligated on R44HL156372: $7,387,301 in federal funding and $2,462,600 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award